Literature DB >> 19458629

Inhibition of KSP by ARRY-520 induces cell cycle block and cell death via the mitochondrial pathway in AML cells.

B Z Carter1, D H Mak, R Woessner, S Gross, W D Schober, Z Estrov, H Kantarjian, M Andreeff.   

Abstract

Kinesin spindle protein (KSP), a microtubule-associated motor protein essential for cell cycle progression, is overexpressed in many cancers and is a potential anti-tumor target. We found that inhibition of KSP by a selective inhibitor, ARRY-520, blocked cell cycle progression, leading to apoptosis in acute myeloid leukemia cell lines that express high levels of KSP. Knockdown of p53, overexpression of XIAP and mutation in caspase-8 did not significantly affect sensitivity to ARRY-520, suggesting that the response is independent of p53, XIAP and the extrinsic apoptotic pathway. Although ARRY-520 induced mitotic arrest in both HL-60 and Bcl-2-overexpressing HL-60Bcl-2 cells, cell death was blunted in HL-60Bcl-2 cells, suggesting that the apoptotic program is executed through the mitochondrial pathway. Accordingly, inhibition of Bcl-2 by ABT-737 was synergistic with ARRY-520 in HL-60Bcl-2 cells. Furthermore, ARRY-520 increased Bim protein levels prior to caspase activation in HL-60 cells. ARRY-520 significantly inhibited tumor growth of xenografts in SCID mice and inhibited AML blast but not normal colony formation, supporting a critical role for KSP in proliferation of leukemic progenitor cells. These results demonstrate that ARRY-520 potently induces cell cycle block and subsequent death in leukemic cells via the mitochondrial pathway and has the potential to eradicate AML progenitor cells.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19458629      PMCID: PMC3593228          DOI: 10.1038/leu.2009.101

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  29 in total

Review 1.  Microtubules as a target for anticancer drugs.

Authors:  Mary Ann Jordan; Leslie Wilson
Journal:  Nat Rev Cancer       Date:  2004-04       Impact factor: 60.716

2.  An inhibitor of the kinesin spindle protein activates the intrinsic apoptotic pathway independently of p53 and de novo protein synthesis.

Authors:  Weikang Tao; Victoria J South; Ronald E Diehl; Joseph P Davide; Laura Sepp-Lorenzino; Mark E Fraley; Kenneth L Arrington; Robert B Lobell
Journal:  Mol Cell Biol       Date:  2006-11-13       Impact factor: 4.272

Review 3.  Development of new cancer therapeutic agents targeting mitosis.

Authors:  Mark R Miglarese; Robert O Carlson
Journal:  Expert Opin Investig Drugs       Date:  2006-11       Impact factor: 6.206

4.  Regulation and targeting of antiapoptotic XIAP in acute myeloid leukemia.

Authors:  B Z Carter; M Milella; T Tsao; T McQueen; W D Schober; W Hu; N M Dean; L Steelman; J A McCubrey; M Andreeff
Journal:  Leukemia       Date:  2003-11       Impact factor: 11.528

5.  p53 status and the efficacy of cancer therapy in vivo.

Authors:  S W Lowe; S Bodis; A McClatchey; L Remington; H E Ruley; D E Fisher; D E Housman; T Jacks
Journal:  Science       Date:  1994-11-04       Impact factor: 47.728

6.  Regulation of Bax activation and apoptotic response to microtubule-damaging agents by p53 transcription-dependent and -independent pathways.

Authors:  Hirohito Yamaguchi; Jiandong Chen; Kapil Bhalla; Hong-Gang Wang
Journal:  J Biol Chem       Date:  2004-07-19       Impact factor: 5.157

7.  Effect of interleukin-1 beta converting enzyme inhibitor on acute myelogenous leukemia progenitor proliferation.

Authors:  Z Estrov; R A Black; P R Sleath; D Harris; Q Van; R LaPushin; E H Estey; M Talpaz
Journal:  Blood       Date:  1995-12-15       Impact factor: 22.113

8.  Triptolide sensitizes AML cells to TRAIL-induced apoptosis via decrease of XIAP and p53-mediated increase of DR5.

Authors:  Bing Z Carter; Duncan H Mak; Wendy D Schober; Martin F Dietrich; Clemencia Pinilla; Lyubomir T Vassilev; John C Reed; Michael Andreeff
Journal:  Blood       Date:  2008-01-10       Impact factor: 22.113

9.  Eg5 steps it up!

Authors:  Megan T Valentine; Polly M Fordyce; Steven M Block
Journal:  Cell Div       Date:  2006-12-15       Impact factor: 5.130

10.  FOXO transcription factors directly activate bim gene expression and promote apoptosis in sympathetic neurons.

Authors:  Jonathan Gilley; Paul J Coffer; Jonathan Ham
Journal:  J Cell Biol       Date:  2003-08-11       Impact factor: 10.539

View more
  13 in total

1.  Distinct gene expression profiles in subsets of chronic lymphocytic leukemia expressing stereotyped IGHV4-34 B-cell receptors.

Authors:  Millaray Marincevic; Mahmoud Mansouri; Meena Kanduri; Anders Isaksson; Hanna Göransson; Karin Ekström Smedby; Jesper Jurlander; Gunnar Juliusson; Fred Davi; Kostas Stamatopoulos; Richard Rosenquist
Journal:  Haematologica       Date:  2010-08-26       Impact factor: 9.941

2.  Phase I/II multicenter study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD4877 in patients with refractory acute myeloid leukemia.

Authors:  H M Kantarjian; S Padmanabhan; W Stock; M S Tallman; G A Curt; J Li; A Osmukhina; K Wu; D Huszar; G Borthukar; S Faderl; G Garcia-Manero; T Kadia; K Sankhala; O Odenike; J K Altman; M Minden
Journal:  Invest New Drugs       Date:  2011-04-15       Impact factor: 3.850

Review 3.  Mitotic catastrophe: a mechanism for avoiding genomic instability.

Authors:  Ilio Vitale; Lorenzo Galluzzi; Maria Castedo; Guido Kroemer
Journal:  Nat Rev Mol Cell Biol       Date:  2011-04-29       Impact factor: 94.444

4.  Synthesis and characterization of tritylthioethanamine derivatives with potent KSP inhibitory activity.

Authors:  Delany Rodriguez; Chinnasamy Ramesh; Lauren H Henson; Lori Wilmeth; Bj K Bryant; Samuel Kadavakollu; Rebecca Hirsch; Johnelle Montoya; Porsha R Howell; Jon M George; David Alexander; Dennis L Johnson; Jeffrey B Arterburn; Charles B Shuster
Journal:  Bioorg Med Chem       Date:  2011-07-30       Impact factor: 3.641

5.  NAT10 regulates mitotic cell fate by acetylating Eg5 to control bipolar spindle assembly and chromosome segregation.

Authors:  Jiaojiao Zheng; Yuqin Tan; Xiaofeng Liu; Chunfeng Zhang; Kunqi Su; Yang Jiang; Jianyuan Luo; Li Li; Xiaojuan Du
Journal:  Cell Death Differ       Date:  2022-02-24       Impact factor: 12.067

6.  Optical Control of Mitosis with a Photoswitchable Eg5 Inhibitor.

Authors:  Anna C Impastato; Andrej Shemet; Nynke A Vepřek; Gadiel Saper; Henry Hess; Lu Rao; Arne Gennerich; Dirk Trauner
Journal:  Angew Chem Int Ed Engl       Date:  2022-01-14       Impact factor: 16.823

7.  Impact of kinesin Eg5 inhibition by 3,4-dihydropyrimidin-2(1H)-one derivatives on various breast cancer cell features.

Authors:  Bruna C Guido; Luciana M Ramos; Diego O Nolasco; Catharine C Nobrega; Bárbara Y G Andrade; Aline Pic-Taylor; Brenno A D Neto; José R Corrêa
Journal:  BMC Cancer       Date:  2015-04-14       Impact factor: 4.430

8.  Identification of cytoskeleton-associated proteins essential for lysosomal stability and survival of human cancer cells.

Authors:  Line Groth-Pedersen; Sonja Aits; Elisabeth Corcelle-Termeau; Nikolaj H T Petersen; Jesper Nylandsted; Marja Jäättelä
Journal:  PLoS One       Date:  2012-10-11       Impact factor: 3.240

9.  A Novel Time-Dependent CENP-E Inhibitor with Potent Antitumor Activity.

Authors:  Akihiro Ohashi; Momoko Ohori; Kenichi Iwai; Tadahiro Nambu; Maki Miyamoto; Tomohiro Kawamoto; Masanori Okaniwa
Journal:  PLoS One       Date:  2015-12-09       Impact factor: 3.240

10.  KSP inhibitor SB743921 inhibits growth and induces apoptosis of breast cancer cells by regulating p53, Bcl-2, and DTL.

Authors:  Li Zhu; Fengjun Xiao; Yue Yu; Hua Wang; Min Fang; Yuefeng Yang; Huiyan Sun; Lisheng Wang; Yuan Sheng
Journal:  Anticancer Drugs       Date:  2016-10       Impact factor: 2.248

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.